Hennion & Walsh Asset Management Inc. Acquires 25,004 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Hennion & Walsh Asset Management Inc. raised its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 60.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,306 shares of the specialty pharmaceutical company's stock after purchasing an additional 25,004 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.12% of Supernus Pharmaceuticals worth $2,398,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in SUPN. Barclays PLC raised its position in Supernus Pharmaceuticals by 88.3% during the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock valued at $3,393,000 after acquiring an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth $791,000. Geode Capital Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock valued at $46,218,000 after purchasing an additional 74,438 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock valued at $987,000 after purchasing an additional 2,121 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in Supernus Pharmaceuticals by 1,508.0% in the second quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company's stock worth $3,287,000 after purchasing an additional 109,088 shares in the last quarter.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 15,000 shares of the business's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the transaction, the senior vice president now directly owns 8,200 shares in the company, valued at $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Georges Gemayel sold 14,213 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares of the company's stock, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock worth $5,660,180 in the last ninety days. 9.30% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Stock Down 0.3 %

SUPN stock traded down $0.13 during mid-day trading on Friday, reaching $37.74. 199,736 shares of the stock traded hands, compared to its average volume of 346,340. The firm has a market capitalization of $2.08 billion, a PE ratio of 35.27 and a beta of 0.90. The business has a 50-day moving average of $36.67 and a two-hundred day moving average of $33.70. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. During the same period in the previous year, the business posted ($0.29) EPS. The company's revenue for the quarter was up 14.2% on a year-over-year basis. On average, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Analyst Ratings Changes

SUPN has been the topic of several recent research reports. Piper Sandler restated a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cantor Fitzgerald initiated coverage on Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an "overweight" rating and a $57.00 target price for the company.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.